Abstract Details

Title Clinical Profile of Newly Diagnosed Children With Tourette Syndrome: Observational Cohort Study of a Large Electronic Medical Records Database

Topic Child Neurology and Developmental Neurology

Presentation(s) P11 - Poster Session 11 (8:00 AM-9:00 AM)

Poster/Presentation
Number 6-005

Objective Describe the demographics and clinical characteristics of children newly diagnosed with Tourette syndrome (TS) using a US electronic medical records database.

Background Small studies indicate that patients with TS can have comorbid psychiatric conditions (eg, anxiety disorders, attention-deficit/hyperactivity disorder [ADHD], and obsessive-compulsive disorder [OCD]). It is estimated that more than half of patients with TS will have ≥1 comorbid psychiatric disorder during their lifetime, but studies on the real-world clinical profile of children/adolescents at the time of TS diagnosis are limited.

Design/Methods

Data were extracted retrospectively (TriNetX Dataworks-USA Network) and included children and adolescents (aged 6-17 years) newly diagnosed with TS (index date [TS diagnosis]; 2011-2021 with ICD-9:307.23 or ICD-10:F95.2). Additionally, at least 1 provider encounter was required during a baseline period (≥6 months prior to index date) and during an 18-month follow-up period.

Results A total of 12,015 children/adolescents with newly diagnosed TS met all selection criteria (71.5% male; 75.1% white; 81.0% non-Hispanic/Latino). Of 6392 with BMI data, 32.7% were overweight/obese. Common comorbid psychiatric disorders were ADHD (38.8%), anxiety (38.2%), OCD (12.4%), and autism spectrum disorder (10.2%). Common baseline TS-related medications were guanfacine (22.1%) and clonidine (11.6%). D2 receptor antagonist use was infrequent during baseline: risperidone (5.5%), aripiprazole (4.0%), quetiapine (1.4%), and haloperidol (1.0%). Of 6 additional medication classes examined, antidepressant (21.4%), ADHD (20.6%), antianxiety (8.9%), and antiseizure (5.9%) medications were most common during the baseline period.

Conclusions A substantial percentage of this large pediatric/adolescent cohort had psychiatric comorbid conditions at the time of TS diagnosis. Future research is warranted to better understand the relationship between TS and these comorbid conditions, as well as the impact of these conditions and other baseline characteristics on safety and efficacy outcomes of TS treatments.

Authors/Disclosures
Kinga Tomczak, MD, PhD (Boston Children's Hospital Tic Disorders and Tourette Syndrome Program) PRESENTER	The institution of Dr. Tomczak has received research support from Emalex Biosciences, Inc.. Dr. Tomczak has a non-compensated relationship as a collabolator with Emalex Biosciences, Inc. that is relevant to AAN interests or activities.
David A. Isaacs, MD (Vanderbilt University Med Center)	The institution of Dr. Isaacs has received research support from NIH NINDS. The institution of Dr. Isaacs has received research support from Teva Branded Pharmaceutical Products, R&D, Inc.. The institution of Dr. Isaacs has received research support from Emalex Biosciences, Inc. Dr. Isaacs has received personal compensation in the range of $0-$499 for serving as a attendee at the annual meeting for Center of Excellence Directors with Tourette Association of America. Dr. Isaacs has a non-compensated relationship as a research collaborator with Emalex Biosciences, Inc that is relevant to AAN interests or activities.
Jason P. Swindle, PhD, MPH	Mr. Swindle has nothing to disclose.
Firas Dabbous, PhD	Dr. Dabbous has received personal compensation for serving as an employee of Thermofisher Scientific.
George Karkanias, PhD (Emalex Biosciences, Inc.)	Dr. Karkanias has received personal compensation for serving as an employee of Emalex Biosciences, Inc.
Sarah Atkinson (Emalex Biosciences)	Sarah Atkinson has received personal compensation for serving as an employee of Emalex Biosciences. Sarah Atkinson has received personal compensation for serving as an employee of World Wide Clinical Trials.
Frederick E. Munschauer III, MD, FAAN (FEMC)	Dr. Munschauer has received personal compensation for serving as an employee of Emalex Biosciences. Dr. Munschauer has stock in Emalex Biosciences.
Faizan Mazhar, PhD	Dr. Mazhar has received personal compensation for serving as an employee of Evidera.
Charlotte A. Pettersson, MSc	Ms. Pettersson has received personal compensation for serving as an employee of PPD Scandinavia AB, part of Thermo Fisher Scientific.
Stephen Wanaski, PhD (Paragon Biosciences)	Dr. Wanaski has received personal compensation for serving as an employee of Paragon Biosciences. Dr. Wanaski has or had stock in Paragon Biosciences.Dr. Wanaski has or had stock in Emalex Biosciences.
Timothy Cunniff, PharmD	Dr. Cunniff has received personal compensation for serving as an employee of Paragon Biosciences. Dr. Cunniff has stock in Harmony Biosciences. Dr. Cunniff has stock in Emalex Biosciences.

��ɫ��

��ɫ��